Single and dual TAF1/FLT3 inhibitors were tested for activity against MOLM13 leukemia cells based on reduction in Cell-titer Glo activity, which corresponds to the number of viable cells, and CellTox Green, which corresponds to the number of dead cells. Here, TAF1 is linked to leukemia.